Buy this Article for $5.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Ticagrelor (Brilinta) is a new antiplatelet drug approved to treat acute coronary syndrome.

 

* When given with low-dosage aspirin, it has been found to reduce thrombotic cardiovascular events and deaths more effectively than clopidogrel (Plavix).

 

* Adverse effects include bleeding and dyspnea. Patients who have recently had an intracranial hemorrhage, are currently bleeding, or who have other risk factors for bleeding shouldn't take ticagrelor.